SOURCE: Axxess Pharma, Inc.

Axxess Pharma, Inc.

November 19, 2014 08:00 ET

Axxess Pharma Receives Health Canada Approval to Sell High Potency Omega-3 Fish Oil Supplement Throughout Canada

Omega-3 Fish Oil to Be Sold Under Globally Recognized TapouT Name

TORONTO, ON--(Marketwired - Nov 19, 2014) - Axxess Pharma Inc. (PINKSHEETS: AXXE), a specialty pharmaceutical and nutritional supplements company, through its wholly owned subsidiary, AllStar Health Brands Inc., is pleased to announce they have now received Health Canada approval to sell their high potency Omega-3 fish oil supplement throughout Canada. The Omega-3 fish oil will be sold under the globally recognized TapouT name with all revenues flowing directly into Axxess Pharma, Inc. The company anticipates generating significant residual sales from the $1 billion Canadian Omega-3 oil market.

Omega-3 fatty acids are some of the most important nutrients to human health. The number of consumers globally who are aware of omega-3 fatty acids and their role in health is high, and the number of people who are specifically consuming Omega-3 for health has increased dramatically over the past few years.

Dr. Daniel Bagi, President of Axxess Pharma, Inc., stated, "We are very excited to receive Health Canada approval to sell our unique high potency Omega-3 fish oil supplements. The source for our premium Omega-3 Fish Oil is Chilean and Peruvian open-ocean sourced anchovy, sardine and mackerel. This ensures no antibiotics or other additives are part of their diet." Dr. Bagi further stated, "The Canadian market for Omega-3 fish oil sales is huge and we expect it to add significantly to US revenues for our Omega-3 fish oil. We anticipate strong sales growth in Canada fueled by aggressive marketing and our globally recognized TapouT name."

Dr. Fred Maese, Senior Consultant of Medical Affairs for Axxess Pharma, Inc., stated, "More than 100 million Americans are at risk for cardiovascular disease, hypertension, stroke, diabetes, obesity, elevated triglycerides, mood disorders, osteoarthritis and premature aging. I strongly recommend a healthy lifestyle and two daily soft-gel caps of the TapouT Premium Omega-3 Fish Oil, resulting in better health and optimal quality of life!" Dr. Maese further stated, "As a cardiologist I endorse this top quality nutraceutical, especially in those with high blood pressure, elevated triglycerides and hardening of the arteries. The American Heart Association and the US Institutes of Health recommend, as part of a healthy diet, at least 1 gram of omega-3 fatty acids a day."

About Axxess Pharma Inc.: Axxess Pharma Inc. is a Nevada Corporation operating through its wholly owned Canadian Subsidiary: Axxess Pharma Canada Inc., headquartered in Toronto. Axxess is a specialty Health Care Products Company dedicated to improving health and quality of life by offering select medicines, nutritional supplements and over the counter remedies all across the Americas. Axxess's goal is to bring additional products to the market and provide new, innovative options for better health spanning areas such as high cholesterol, blood pressure, acute pain -- to optimal health management through improved nutritional supplements. To learn more about our new products TapouT Extreme Muscle Growth and TapouT Muscle Recovery, please visit: and

About TapouT: TapouT is a lifestyle brand that has been at the forefront of Mixed Martial Arts since its inception in 1997. The label is rapidly growing into other sports and categories, offering merchandise for men, women and kids. TapouT has endorsed high-profile professional athletes who compete in sports such as basketball, football, baseball, stock car racing, and most famously, MMA. TapouT is sold in sporting goods stores, specialty retailers and online. For updates and more information, please visit

Safe Harbor Statement

Statements about the Company's future expectations and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby.

The above information contains information relating to the Company that is based on the beliefs of the Company and/or its management, as well as assumptions made by any information currently available to the Company or its management. When used in this document, the words "anticipate," "estimate," "expect," "intend," "plans," "projects," and similar expressions, as they relate to the Company or its management, are intended to identify forward-looking statements. Such statements reflect the current view of the Company regarding future events and are subject to certain risks, uncertainties and assumptions, including the risks and uncertainties noted. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove to be incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, expected, intended or projected. In each instance, forward-looking information should be considered in light of the accompanying meaningful cautionary statements herein. Factors that could cause results to differ include, but are not limited to, successful performance of internal plans, the impact of competitive services and pricing and general economic risks and uncertainties.

Contact Information